NASDAQ:KRTX
Karuna Therapeutics, Inc. Stock News
$329.83
+0 (+0%)
At Close: Apr 29, 2024
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
12:11pm, Friday, 23'rd Feb 2024
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
Bullish Continuation in '24? 3 Market Areas to Watch
02:17pm, Wednesday, 10'th Jan 2024
Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
Yes Virginia, There Is a Santa Claus Rally
06:47pm, Tuesday, 26'th Dec 2023
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
12:46pm, Tuesday, 26'th Dec 2023
Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies
04:10pm, Saturday, 23'rd Dec 2023
Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.
Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal
06:29pm, Friday, 22'nd Dec 2023
Michael Yee, Jefferies Senior Biotech Analyst, joins 'Fast Money' to talk a possible boom ahead for the biotech sector.
Bristol Myers Squibb to buy Karuna Therapeutics for $14 billion in cash
01:27pm, Friday, 22'nd Dec 2023
Stephanie Link and Jim Lebenthal join 'Halftime Report' to discuss Bristol Myers Squibb's latest announcement to buy Karuna Therapeutics for $14 billion.
Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal
01:14pm, Friday, 22'nd Dec 2023
Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the compa
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
12:45pm, Friday, 22'nd Dec 2023
U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 50
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
12:40pm, Friday, 22'nd Dec 2023
Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
09:58am, Friday, 22'nd Dec 2023
Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.
A Major Acquisition and Other News Ahead of the Holiday Weekend
09:40am, Friday, 22'nd Dec 2023
Before U.S. markets opened on Friday, the Bureau of Economic Analysis released its personal income and spending report for November.
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
09:06am, Friday, 22'nd Dec 2023
Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.
Bristol Myers to buy Karuna Therapeutics for $14B
08:40am, Friday, 22'nd Dec 2023
Karuna's crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.
Bristol Myers to buy Karuna Therapeutics for $14 billion
07:39am, Friday, 22'nd Dec 2023
CNBC's Joe Kernen reports on the latest news.
